K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.
What happened
FDA reviewed records the company submitted after a March 3, 2023 request and found significant CGMP violations. The company did not show identity testing of each shipment and lot of high-risk components, including glycerin and sorbitol solution, for diethylene glycol (DEG) or ethylene glycol (EG), and its quality unit did not adequately approve or reject components.
What FDA found
The company did not test each incoming shipment and lot of high-risk components, such as glycerin and sorbitol solution, to verify identity and screen for DEG or EG contamination.
21 CFR 211.84(d)(1)The quality unit lacked effective authority to approve or reject components and did not adequately oversee the materials system.
21 CFR 211.22(a)
What FDA wants
FDA tells the company to respond in writing within 30 working days with corrective actions and commitments, including DEG/EG test results within 30 calendar days, a risk assessment, CAPA, material-system review, and quality-unit remediation. If corrective actions cannot be completed within 15 working days, the company must state the reasons and provide a completion schedule.
Who should pay attention
- brands that use this contract manufacturer for OTC drugs
- companies sourcing glycerin or sorbitol solution with incomplete identity testing
- U.S. importers and distributors of OTC drug products
This is a summary. Read the original letter on fda.gov.